在接受四个月的卡巴拉汀治疗后，阿尔茨海默病患者后扣带回中N-乙酰天门冬氨酸与肌酸的比例降低与认知功能相关。
Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
作者信息
Penner Jacob, Wells Jennie L, Borrie Michael J, Woolmore-Goodwin Sarah M, Bartha Robert
机构信息
Centre for Functional and Metabolic Mapping (CFMM), Robarts Research Institute, and Department of Medical Biophysics, University of Western Ontario, London, Ont., Canada.
出版信息
Dement Geriatr Cogn Disord. 2015;39(1-2):68-80. doi: 10.1159/000367685. Epub 2014 Oct 24.
AIM
To determine whether 4 months of rivastigmine treatment would result in metabolic changes and whether metabolic changes correlate with changes in cognition in people with Alzheimer's disease (AD).
METHODS
Magnetic resonance spectra were acquired from the posterior cingulate cortex of subjects with AD at 3 T. Magnetic resonance imaging scans and cognitive tests were performed before and 4 months after the beginning of the treatment. Metabolite concentrations were quantified and used to calculate the metabolite ratios.
RESULTS
On average, the N-acetylaspartate/creatine (NAA/Cr) ratio decreased by 12.7% following 4 months of rivastigmine treatment, but changes in the NAA/Cr ratio correlated positively with changes in Mini-Mental State Examination scores.
CONCLUSION
This positive correlation between changes in NAA/Cr and changes in cognitive performance suggests that the NAA/Cr ratio could be an objective indicator of a response to rivastigmine treatment.
目的
确定4个月的卡巴拉汀治疗是否会导致代谢变化，以及代谢变化是否与阿尔茨海默病（AD）患者的认知变化相关。
方法
在3T条件下从AD患者的后扣带回皮质获取磁共振波谱。在治疗开始前和开始4个月后进行磁共振成像扫描和认知测试。对代谢物浓度进行定量并用于计算代谢物比率。
结果
平均而言，卡巴拉汀治疗4个月后，N-乙酰天门冬氨酸/肌酸（NAA/Cr）比率下降了12.7%，但NAA/Cr比率的变化与简易精神状态检查表评分的变化呈正相关。
结论
NAA/Cr变化与认知表现变化之间的这种正相关表明，NAA/Cr比率可能是对卡巴拉汀治疗反应的客观指标。
Zotero 插件